Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Case of GLP-1 Receptor Agonist-Induced Lithium Neurotoxicity.

Journal of psychiatric practice·2026

Same author

Diagnostic Challenges in Distinguishing Huntington Disease From Tardive Dyskinesia.

The primary care companion for CNS disorders·2025

Same author

Protocol to study the contribution of tendon lineage in the development of mouse temporomandibular joint condylar cartilage using 3D visualization.

STAR protocols·2025

Same author

Correction: Evaluating factors impacting early career physician-scientists' decisions to continue research careers in the United States of America.

BMC medical education·2025

Same author

Evaluating factors impacting early career physician-scientists' decisions to continue research careers in the United States of America.

BMC medical education·2025

Same author

Direct sensing of dietary ω-6 linoleic acid through FABP5-mTORC1 signaling.

Science (New York, N.Y.)·2025

Search research articles

Related Experiment Video

Updated: Feb 22, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Targeting Metabolic Vulnerabilities in Glioblastoma: a Framework for Multi-node Combination Therapy.

Vishal Gokani¹, Anuhya Kotta¹, Venkata Repaka²

¹Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Current Oncology Reports

|February 20, 2026

Summary

Targeting cancer cell metabolism offers a promising adjuvant therapy for glioblastoma (GBM). Combination metabolic therapies show synergistic effects by overcoming resistance mechanisms, suggesting improved patient outcomes with further clinical trials.

Keywords:

Combination therapy Glioblastoma Glutaminolysis Glycolysis Lipid metabolism Metabolic therapy Mitochondrial metabolism Nucleotide synthesis Redox stress

More Related Videos

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment

Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Feb 22, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment

Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment

Published on: March 1, 2024

Area of Science:

Oncology
Metabolic Pathways
Cancer Therapeutics

Background:

Glioblastoma (GBM) presents a poor prognosis with standard treatments.
Targeted metabolic therapy is being explored as an adjuvant treatment for GBM.

Purpose of the Study:

To review the rationale for metabolic therapy in GBM.
To identify resistance mechanisms to metabolic therapies.
To explore synergistic combination strategies for metabolic therapy in GBM.

Main Methods:

Literature review of preclinical and clinical studies on metabolic therapy in GBM.
Analysis of metabolic pathways critical for GBM cell survival and proliferation.
Evaluation of resistance mechanisms and combination strategies.

Main Results:

Individual targeting of metabolic enzymes (glycolysis, glutaminolysis, lipid metabolism, etc.) shows promise in preclinical studies.
GBM cells develop resistance to monotherapy by utilizing alternative metabolic pathways.
Combination metabolic therapies targeting multiple nodes synergistically inhibit tumor growth and bypass resistance.

Conclusions:

Metabolic monotherapy has limited success in GBM due to resistance.
Synergistic combination metabolic therapies are more promising for overcoming resistance.
Combination regimens delivered with standard care may improve patient outcomes, warranting larger clinical trials.